DNTH · Insider Trading
Dianthus Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by DNTH officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-18 | Edward Carr | CHIEF ACCOUNTING OFFICER | MIXED | — | −$1.67M |
| 2026-09-03 | Simrat Randhawa | EVP, Head of R&D | MIXED | — | −$1.98M |
| 2026-08-19 | Simon Read | Director | MIXED | — | −$275.55K |
| 2026-08-14 | Adam M Veness | SVP, General Counsel and Sec. | M | +15,000 | +$272.55K |
| 2026-08-11 | Simon Read | Director | MIXED | — | −$253.25K |
| 2026-08-11 | Anne McGeorge | Director | MIXED | — | −$747.82K |
| 2026-08-11 | Adam M Veness | SVP, General Counsel and Sec. | MIXED | — | −$1.85M |
| 2026-08-07 | Marino Garcia | CEO AND PRESIDENT | MIXED | — | −$16.54M |
| 2026-08-07 | Marino Garcia | CEO AND PRESIDENT | MIXED | — | −$16.54M |
| 2026-07-13 | Ryan Savitz | EVP, CFO & CBO | MIXED | — | −$2.48M |
| 2026-06-18 | Adam M Veness | SVP, General Counsel and Sec. | MIXED | — | −$1.89M |
| 2026-06-02 | Simrat Randhawa | EVP, Head of R&D | MIXED | — | −$1.90M |
| 2026-05-22 | Sujay Kango | Director | A | +6,090 deriv. | — |
| 2026-05-22 | Alison Frances Lawton | Director | A | +6,090 deriv. | — |
| 2026-05-22 | Paula Soteropoulos | Director | A | +6,090 deriv. | — |
| 2026-05-22 | Anne McGeorge | Director | A | +6,090 deriv. | — |
| 2026-05-22 | Steven J. Romano | Director | A | +6,090 deriv. | — |
| 2026-05-22 | Simon Read | Director | A | +6,090 deriv. | — |
| 2026-05-22 | Jonathan Violin | Director | A | +6,090 deriv. | — |
| 2026-05-11 | Paula Soteropoulos | Director | MIXED | — | −$46.14K |
| 2026-04-10 | Ryan Savitz | EVP, CFO & CBO | MIXED | — | −$591.80K |
| 2026-04-01 | Paula Soteropoulos | Director | MIXED | — | −$42.93K |
| 2026-04-01 | Ryan Savitz | EVP, CFO & CBO | MIXED | — | −$8.15M |
| 2026-03-26 | Paula Soteropoulos | Director | MIXED | — | −$1.92M |
| 2026-03-17 | Marino Garcia | CEO AND PRESIDENT | M | +65,292 | +$499.97K |
| 2026-03-13 | Simrat Randhawa | EVP, Head of R&D | MIXED | — | −$2.14M |
| 2026-03-13 | Marino Garcia | CEO AND PRESIDENT | MIXED | — | −$9.19M |
| 2026-03-13 | Edward Carr | CHIEF ACCOUNTING OFFICER | MIXED | — | −$2.67M |
| 2026-02-04 | Simrat Randhawa | EVP, Head of R&D | A | +150,000 deriv. | — |
| 2026-02-04 | Marino Garcia | CEO AND PRESIDENT | A | +355,000 deriv. | — |
| 2026-02-04 | Adam M Veness | SVP, General Counsel and Sec. | A | +100,000 deriv. | — |
| 2026-02-04 | Ryan Savitz | EVP, CFO & CBO | A | +150,000 deriv. | — |
| 2026-02-04 | Edward Carr | CHIEF ACCOUNTING OFFICER | A | +55,000 deriv. | — |
| 2025-12-05 | Ryan Savitz | CFO & CBO | MIXED | — | −$734.80K |
| 2025-11-14 | Simrat Randhawa | EVP, Head of R&D | MIXED | — | −$4.38M |
| 2025-10-03 | Marino Garcia | CEO AND PRESIDENT | A | +120,000 deriv. | — |
| 2025-09-25 | Ryan Savitz | CFO & CBO | A | +60,000 deriv. | — |
| 2025-09-25 | Simrat Randhawa | CHIEF MEDICAL OFFICER | A | +60,000 deriv. | — |
| 2025-09-11 | Ryan Savitz | CFO & CBO | MIXED | — | −$531.20K |
| 2025-05-22 | Jonathan Violin | Director | A | +12,500 deriv. | — |
| 2025-05-22 | Paula Soteropoulos | Director | A | +12,500 deriv. | — |
| 2025-05-22 | Anne McGeorge | Director | A | +12,500 deriv. | — |
| 2025-05-22 | Alison Frances Lawton | Director | A | +12,500 deriv. | — |
| 2025-05-22 | Steven J. Romano | Director | A | +12,500 deriv. | — |
| 2025-05-22 | Simon Read | Director | A | +25,000 deriv. | — |
| 2025-03-05 | Sujay Kango | Director | A | +25,000 deriv. | — |
| 2025-02-04 | Simrat Randhawa | CHIEF MEDICAL OFFICER | A | +150,000 deriv. | — |
| 2025-02-04 | Ryan Savitz | CFO & CBO | A | +150,000 deriv. | — |
| 2025-02-04 | Adam M Veness | SVP, General Counsel and Sec. | A | +100,000 deriv. | — |
| 2025-02-04 | Marino Garcia | CEO AND PRESIDENT | A | +340,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Marino Garcia | CEO AND PRESIDENT | 197,001 | $14.20M |
| Adam M Veness | SVP, General Counsel and Sec. | 15,000 | $1.08M |
| Anne McGeorge | Director | 7,750 | $558.70K |
| Simrat Randhawa | EVP, Head of R&D | 4,000 | $288.36K |
| Edward Carr | CHIEF ACCOUNTING OFFICER | 1,800 | $129.76K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the DNTH quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.